MRPL46

Summary

MRPL46 (mitochondrial ribosomal protein L46, HGNC:1192) is a protein-coding gene on chromosome 15q25.3, encoding Large ribosomal subunit protein mL46 (Q9H2W6). It is a selective cancer dependency (DepMap: 28.9% of cell lines).

Mammalian mitochondrial ribosomal proteins are encoded by nuclear genes and help in protein synthesis within the mitochondrion. Mitochondrial ribosomes (mitoribosomes) consist of a small 28S subunit and a large 39S subunit. They have an estimated 75% protein to rRNA composition compared to prokaryotic ribosomes, where this ratio is reversed. Another difference between mammalian mitoribosomes and prokaryotic ribosomes is that the latter contain a 5S rRNA. Among different species, the proteins comprising the mitoribosome differ greatly in sequence, and sometimes in biochemical properties, which prevents easy recognition by sequence homology. This gene encodes a 39S subunit protein.

Source: NCBI Gene 26589 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 58 total
• Cancer dependency (DepMap): dependent in 28.9% of screened cell lines
• MANE Select transcript: NM_022163

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1192
Approved symbol	MRPL46
Name	mitochondrial ribosomal protein L46
Location	15q25.3
Locus type	gene with protein product
Status	Approved
Aliases	LIECG2, P2ECSL, mL46
Ensembl gene	ENSG00000259494
Ensembl biotype	protein_coding
OMIM	611851
Entrez	26589

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 5 protein_coding, 2 nonsense_mediated_decay, 1 retained_intron

ENST00000312475, ENST00000558531, ENST00000558660, ENST00000559538, ENST00000560703, ENST00000887805, ENST00000887806, ENST00000962924

RefSeq mRNA: 1 — MANE Select: NM_022163 NM_022163

CCDS: CCDS10341

Canonical transcript exons

ENST00000312475 — 4 exons

Exon	Start	End
ENSE00001186022	88459478	88459863
ENSE00001592515	88467150	88467388
ENSE00003609738	88465587	88465773
ENSE00003649655	88464703	88464876

Expression profiles

Bgee: expression breadth ubiquitous, 140 present calls, max score 96.05.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 20.1744 / max 118.0912, expressed in 1809 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
151383	20.1744	1809

Top tissues by expression

140 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adrenal tissue	UBERON:0018303	96.05	gold quality
heart left ventricle	UBERON:0002084	95.43	gold quality
apex of heart	UBERON:0002098	94.98	gold quality
right adrenal gland cortex	UBERON:0035827	94.78	gold quality
right adrenal gland	UBERON:0001233	94.76	gold quality
gastrocnemius	UBERON:0001388	94.37	gold quality
left adrenal gland	UBERON:0001234	94.28	gold quality
muscle of leg	UBERON:0001383	94.14	gold quality
skeletal muscle organ	UBERON:0014892	94.05	gold quality
left adrenal gland cortex	UBERON:0035825	93.81	gold quality
hindlimb stylopod muscle	UBERON:0004252	93.76	gold quality
adrenal gland	UBERON:0002369	93.63	gold quality
heart	UBERON:0000948	93.20	gold quality
right lobe of liver	UBERON:0001114	93.01	gold quality
liver	UBERON:0002107	92.50	gold quality
mucosa of transverse colon	UBERON:0004991	92.28	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	91.76	gold quality
right atrium auricular region	UBERON:0006631	91.74	gold quality
skeletal muscle tissue	UBERON:0001134	91.68	gold quality
muscle tissue	UBERON:0002385	91.10	gold quality
adult mammalian kidney	UBERON:0000082	90.77	gold quality
prefrontal cortex	UBERON:0000451	90.65	gold quality
rectum	UBERON:0001052	89.65	gold quality
frontal cortex	UBERON:0001870	89.49	gold quality
esophagus mucosa	UBERON:0002469	89.18	gold quality
transverse colon	UBERON:0001157	89.16	gold quality
placenta	UBERON:0001987	89.13	gold quality
body of stomach	UBERON:0001161	89.11	gold quality
left testis	UBERON:0004533	88.93	gold quality
fundus of stomach	UBERON:0001160	88.80	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.19

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): YY1

miRNA regulators (miRDB)

3 targeting MRPL46, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4316	99.37	65.75	1360
HSA-MIR-377-3P	99.37	70.18	1905
HSA-MIR-2467-5P	97.36	67.71	991

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 28.9% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 1)

• Expression is enriched in testis. Positioned to chromosome 15q24 by radiation hybrid mapping. (PMID:11761714)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	mrpl46	ENSDARG00000016307
mus_musculus	Mrpl46	ENSMUSG00000030612
rattus_norvegicus	Mrpl46	ENSRNOG00000018547
drosophila_melanogaster	mRpL46	FBGN0035272
caenorhabditis_elegans		WBGENE00021935

Protein

Protein identifiers

Large ribosomal subunit protein mL46 — Q9H2W6 (reviewed: Q9H2W6)

Alternative names: 39S ribosomal protein L46, mitochondrial, P2ECSL

All UniProt accessions (4): A0A087WT51, A0A087WT90, H0YN64, Q9H2W6

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Component of the mitochondrial large ribosomal subunit (mt-LSU). Mature mammalian 55S mitochondrial ribosomes consist of a small (28S) and a large (39S) subunit. The 28S small subunit contains a 12S ribosomal RNA (12S mt-rRNA) and 30 different proteins. The 39S large subunit contains a 16S rRNA (16S mt-rRNA), a copy of mitochondrial valine transfer RNA (mt-tRNA(Val)), which plays an integral structural role, and 52 different proteins. mL46 is located at the central protuberance.

Subcellular location. Mitochondrion.

Similarity. Belongs to the mitochondrion-specific ribosomal protein mL46 family.

RefSeq proteins (1): NP_071446* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR015797	NUDIX_hydrolase-like_dom_sf	Homologous_superfamily
IPR021757	Ribosomal_mL46_N	Domain
IPR033650	Ribosomal_mL46_NUDIX	Domain
IPR040008	Ribosomal_mL46	Family

Pfam: PF11788

UniProt features (31 total): strand 15, helix 9, turn 2, transit peptide 1, chain 1, modified residue 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

82 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
7OF0	ELECTRON MICROSCOPY	2.2
7QI4	ELECTRON MICROSCOPY	2.21
8RRI	ELECTRON MICROSCOPY	2.4
8QU5	ELECTRON MICROSCOPY	2.42
9OLF	ELECTRON MICROSCOPY	2.46
7OF7	ELECTRON MICROSCOPY	2.5
7PO4	ELECTRON MICROSCOPY	2.56
6ZM6	ELECTRON MICROSCOPY	2.59
7O9M	ELECTRON MICROSCOPY	2.6
7OF6	ELECTRON MICROSCOPY	2.6
9CN3	ELECTRON MICROSCOPY	2.62
7QI5	ELECTRON MICROSCOPY	2.63
7OF2	ELECTRON MICROSCOPY	2.7
7OF3	ELECTRON MICROSCOPY	2.7
7OF4	ELECTRON MICROSCOPY	2.7
9PR4	ELECTRON MICROSCOPY	2.77
9PRA	ELECTRON MICROSCOPY	2.83
8ANY	ELECTRON MICROSCOPY	2.85
6ZM5	ELECTRON MICROSCOPY	2.89
7ODR	ELECTRON MICROSCOPY	2.9
7OF5	ELECTRON MICROSCOPY	2.9
8K2A	ELECTRON MICROSCOPY	2.9
8OIT	ELECTRON MICROSCOPY	2.9
9PGL	ELECTRON MICROSCOPY	2.9
9PGF	ELECTRON MICROSCOPY	2.93
6VMI	ELECTRON MICROSCOPY	2.96
6VLZ	ELECTRON MICROSCOPY	2.97
7QI6	ELECTRON MICROSCOPY	2.98
9PSM	ELECTRON MICROSCOPY	2.98
8QSJ	ELECTRON MICROSCOPY	3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H2W6-F1	80.43	0.48

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 230

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-5368286	Mitochondrial translation initiation
R-HSA-5389840	Mitochondrial translation elongation
R-HSA-5419276	Mitochondrial translation termination
R-HSA-9937383	Mitochondrial ribosome-associated quality control
R-HSA-392499	Metabolism of proteins
R-HSA-5368287	Mitochondrial translation
R-HSA-72766	Translation

MSigDB gene sets: 133 (showing top): GOBP_MITOCHONDRIAL_TRANSLATION, GOBP_TRANSLATION, GOMF_STRUCTURAL_CONSTITUENT_OF_RIBOSOME, GOCC_MITOCHONDRIAL_ENVELOPE, TIEN_INTESTINE_PROBIOTICS_24HR_UP, GOCC_LARGE_RIBOSOMAL_SUBUNIT, GOCC_RIBOSOME, GOCC_ORGANELLAR_RIBOSOME, GOCC_MITOCHONDRIAL_MATRIX, GAVIN_FOXP3_TARGETS_CLUSTER_T7, GOCC_ORGANELLE_INNER_MEMBRANE, GOCC_RIBOSOMAL_SUBUNIT, GOCC_RIBONUCLEOPROTEIN_COMPLEX, GOCC_MITOCHONDRIAL_PROTEIN_CONTAINING_COMPLEX, MANALO_HYPOXIA_DN

GO Biological Process (1): mitochondrial translation (GO:0032543)

GO Molecular Function (1): structural constituent of ribosome (GO:0003735)

GO Cellular Component (8): nucleoplasm (GO:0005654), mitochondrion (GO:0005739), mitochondrial inner membrane (GO:0005743), mitochondrial large ribosomal subunit (GO:0005762), cytosol (GO:0005829), cell junction (GO:0030054), ribosome (GO:0005840), ribonucleoprotein complex (GO:1990904)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Mitochondrial translation	4
Translation	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
cytoplasm	2
mitochondrion	1
translation	1
mitochondrial gene expression	1
structural molecule activity	1
ribosome	1
nuclear lumen	1
intracellular membrane-bounded organelle	1
organelle inner membrane	1
mitochondrial membrane	1
organellar large ribosomal subunit	1
mitochondrial ribosome	1
mitochondrial protein-containing complex	1
intracellular membraneless organelle	1
protein-containing complex	1

Protein interactions and networks

STRING

2462 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MRPL46	MRPL1	Q9BYD6	618
MRPL46	MRPL40	Q9NQ50	593
MRPL46	MRPL54	Q6P161	585
MRPL46	MRPL44	Q9H9J2	573
MRPL46	RANBP6	O60518	546
MRPL46	AGFG2	O95081	544
MRPL46	MRPS9	P82933	539
MRPL46	MRPS14	O60783	514
MRPL46	SRP72	O76094	505
MRPL46	MRPS15	P82914	489
MRPL46	DARS2	Q6PI48	472
MRPL46	MRPL53	Q96EL3	467
MRPL46	MRPS11	P82912	463
MRPL46	MRPL36	Q9P0J6	460
MRPL46	KATNB1	Q9BVA0	458

IntAct

115 interactions, top by confidence:

A	B	Type	Score
NDUFS3	NDUFS8	psi-mi:“MI:0914”(association)	0.730
MRPL37	HSPD1	psi-mi:“MI:0914”(association)	0.710
MRPS30	GTPBP10	psi-mi:“MI:0914”(association)	0.640
ETFRF1	NDUFAB1	psi-mi:“MI:0914”(association)	0.640
LIN28A	IGF2BP3	psi-mi:“MI:0914”(association)	0.640
NP	KPNA6	psi-mi:“MI:0914”(association)	0.550
MRPL50	GTPBP10	psi-mi:“MI:0914”(association)	0.530
MRPL46	NDUFAB1	psi-mi:“MI:0914”(association)	0.530
MRPL10	ZZEF1	psi-mi:“MI:0914”(association)	0.530
MRPL42	GATC	psi-mi:“MI:0914”(association)	0.530
MRPL41	MRPL3	psi-mi:“MI:0914”(association)	0.530
MRPL2	GTPBP10	psi-mi:“MI:0914”(association)	0.530
MRPL46	MRPL55	psi-mi:“MI:0914”(association)	0.530
MRPL13	GTPBP10	psi-mi:“MI:0914”(association)	0.530
MRPL18	GTPBP10	psi-mi:“MI:0914”(association)	0.530
NDUFAB1	MIEF1	psi-mi:“MI:0915”(physical association)	0.490
Rpl35	RPS6	psi-mi:“MI:0914”(association)	0.350
RPL10	RPS6	psi-mi:“MI:0914”(association)	0.350
Brwd3	WDR91	psi-mi:“MI:0914”(association)	0.350
Srp72		psi-mi:“MI:0914”(association)	0.350

BioGRID (255): MRPL46 (Affinity Capture-MS), MRPL46 (Affinity Capture-MS), MRPL46 (Affinity Capture-MS), MRPL48 (Affinity Capture-MS), MRPL40 (Affinity Capture-MS), LYRM5 (Affinity Capture-MS), MRPL55 (Affinity Capture-MS), MGME1 (Affinity Capture-MS), NDUFAB1 (Affinity Capture-MS), MRPL46 (Affinity Capture-MS), MRPL46 (Affinity Capture-MS), MRPL46 (Affinity Capture-MS), MRPL46 (Affinity Capture-MS), MRPL46 (Affinity Capture-MS), MRPL46 (Affinity Capture-MS)

ESM2 similar proteins: A9UMP7, B0BM20, B0S6U7, D6WIX5, O95801, P19686, P19687, P34384, P42704, P57075, Q02108, Q0IHP3, Q13057, Q14C51, Q2KI62, Q2KIS2, Q32LU7, Q32N55, Q3U2U7, Q3V3E1, Q4G069, Q4ZHS0, Q5EA11, Q5M9G9, Q5R8E4, Q5RBU2, Q5REY8, Q5SGE0, Q66K14, Q6DJ55, Q6PA48, Q6PB66, Q80Y81, Q8BYI6, Q8CGS5, Q8HY87, Q8N159, Q8R4H7, Q91YM4, Q96DB5

Diamond homologs: O94398, Q5RBU2, Q7S1Z3, Q9H2W6, P36528, Q3SZ22, Q5RK00, Q9EQI8

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
MRPL46	“form complex”	“39S mitochondrial large ribosomal subunit”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 106 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Mitochondrial ribosome-associated quality control	32	51.0×	6e-46
Mitochondrial translation initiation	29	47.8×	1e-40
Mitochondrial translation elongation	29	47.8×	1e-40
Mitochondrial translation	26	46.5×	5e-36
Mitochondrial translation termination	29	41.4×	1e-38
Translation	28	22.6×	2e-29
Mitochondrial protein degradation	6	8.9×	3e-03

GO biological processes:

GO term	Partners	Fold	FDR
mitochondrial translation	31	58.5×	2e-45
translation	22	24.6×	2e-22

Disease & clinical

Clinical variants and AI predictions

ClinVar

58 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	49
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1268 predictions. Top by Δscore:

Variant	Effect	Δscore
15:88462737:C:CT	acceptor_gain	1.0000
15:88465557:T:A	donor_gain	1.0000
15:88465629:C:CA	donor_gain	1.0000
15:88465636:ATCTT:A	donor_gain	1.0000
15:88465637:T:C	donor_gain	1.0000
15:88465640:T:TA	donor_gain	1.0000
15:88467175:T:TA	donor_gain	1.0000
15:88459861:TTT:T	acceptor_gain	0.9900
15:88459861:TTTCT:T	acceptor_loss	0.9900
15:88459862:TTC:T	acceptor_loss	0.9900
15:88459863:TC:T	acceptor_loss	0.9900
15:88459864:C:A	acceptor_loss	0.9900
15:88459864:C:CC	acceptor_gain	0.9900
15:88459865:T:A	acceptor_loss	0.9900
15:88460155:AGTT:A	donor_gain	0.9900
15:88461290:A:AC	donor_gain	0.9900
15:88462738:A:T	acceptor_gain	0.9900
15:88464698:CCCA:C	donor_loss	0.9900
15:88464699:CCA:C	donor_loss	0.9900
15:88464700:CAC:C	donor_loss	0.9900
15:88464701:A:AG	donor_loss	0.9900
15:88464702:CCT:C	donor_loss	0.9900
15:88464881:A:T	acceptor_gain	0.9900
15:88465585:ACC:A	donor_loss	0.9900
15:88465586:CCT:C	donor_loss	0.9900
15:88465633:CATAT:C	donor_gain	0.9900
15:88465636:AT:A	donor_gain	0.9900
15:88465663:AT:A	donor_gain	0.9900
15:88465664:T:TA	donor_gain	0.9900
15:88465769:TCAAT:T	acceptor_gain	0.9900

AlphaMissense

1802 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:88459693:A:G	W254R	0.984
15:88459693:A:T	W254R	0.984
15:88459757:G:C	F232L	0.981
15:88459757:G:T	F232L	0.981
15:88459759:A:G	F232L	0.981
15:88464723:C:G	R190P	0.972
15:88459691:C:A	W254C	0.969
15:88459691:C:G	W254C	0.969
15:88459747:C:G	A236P	0.969
15:88464839:C:A	R151S	0.969
15:88464839:C:G	R151S	0.969
15:88464781:A:G	W171R	0.968
15:88464781:A:T	W171R	0.968
15:88459746:G:T	A236E	0.964
15:88464729:G:T	A188D	0.961
15:88464840:C:A	R151M	0.961
15:88467214:C:G	R55P	0.958
15:88459628:A:C	F275L	0.957
15:88459628:A:T	F275L	0.957
15:88459630:A:G	F275L	0.957
15:88464840:C:G	R151T	0.955
15:88467230:C:G	A50P	0.954
15:88459638:A:T	V272D	0.952
15:88459827:G:T	P209H	0.951
15:88464822:A:G	L157P	0.946
15:88467229:G:T	A50E	0.946
15:88459758:A:G	F232S	0.941
15:88467224:A:G	C52R	0.941
15:88467233:C:G	G49R	0.941
15:88459755:A:G	F233S	0.936

dbSNP variants (sampled 300 via entrez): RS1000088800 (15:88466395 T>G), RS1000183225 (15:88466131 A>C), RS1000531418 (15:88460479 T>C), RS1000988299 (15:88459727 G>C,T), RS1000998180 (15:88460003 A>G,T), RS1001131473 (15:88461759 C>T), RS1001449830 (15:88463124 G>C), RS1001503495 (15:88463376 C>T), RS1001747901 (15:88469016 A>G), RS1001897891 (15:88465075 G>A), RS1002505035 (15:88461973 G>A), RS1002561198 (15:88462562 G>C), RS1002692391 (15:88467364 A>G), RS1003006136 (15:88467550 G>A,C,T), RS1004358900 (15:88465189 G>C)

Disease associations

OMIM: gene MIM:611851 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Acetaminophen	affects cotreatment, decreases expression	3
sodium arsenite	affects binding, increases reaction, decreases expression	2
Valproic Acid	affects expression, increases expression	2
aristolochic acid I	increases expression	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
trichostatin A	affects expression	1
perfluorooctanoic acid	increases expression	1
potassium chromate(VI)	decreases expression, affects cotreatment	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
abrine	increases expression	1
bisphenol S	affects expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Aspirin	increases expression	1
Ivermectin	decreases expression	1
Lipopolysaccharides	decreases expression, affects cotreatment	1
Plant Extracts	affects cotreatment, increases expression	1
Smoke	decreases expression	1
Cyclosporine	decreases expression	1
Aflatoxin B1	decreases methylation	1
Cadmium Chloride	decreases expression	1
Okadaic Acid	decreases expression	1
Copper Sulfate	decreases expression	1
Lactic Acid	decreases expression	1
Particulate Matter	decreases expression, increases abundance	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer